Revenue from operations grew 13.4% year-on-year to ₹2,269.8 crore from ₹2,001.9 crore in Q2 FY25, driven by strong growth across key therapeutic segments and continued momentum in both domestic and international markets.
Revenue from operations grew 13.4% year-on-year to ₹2,269.8 crore from ₹2,001.9 crore in Q2 FY25, driven by strong growth across key therapeutic segments and continued momentum in both domestic and international markets.